Clinical Trial Update: Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates neoadjuvant adebrelimab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma; the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: Zhigang Li | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING